Biotechnology Healthcare - June 2008 - (Page 62) INDEX BIOTECHNOLOGY HEALTHCARE’s 2007 Editorial Index Authors of feature articles are listed alphabetically. Multiple articles by a single author or under a topic are listed chronologically by issue month and then by page number. Feature article titles are set in boldface. Suggested basic form for references: Biotechnol Healthcare. 2007;4(issue):page(s) Carlson, Bob. A Wish List for Molecular Tests. Dec.: 46–53 Clough, Jeff. Demonstrating the Value of Biologics: A Call to Action. Aug.: 33–42 Haas, J. Scott; Moskowitz, Eric J. Health Technology Assessment in Canada and the United States: The Case of Biologics. April: 47–51 Jacobs, Jack. A Renewed Emphasis on Therapeutic Angiogenesis Research for CAD. Oct.: 49–54 Kober, Scott. Taking Control of Compliance. June: 39–42 Lash, Stephen. Learning To Love Your Specialty Pharmacy. Oct.: 45–48 Mullen, Patrick. The Arrival of Average Sales Price. June: 48–53 Mullen, Patrick. Where VC Fears To Tread. Oct.: 29–35 Otrompke, John J. Are We There Yet? Seeking the Value of Pharmacogenetics in Cardiovascular Care. Feb.: 61–62 Otrompke, John J. Patent Pending: Biotech Awaits Answers on New Trends. Aug.: 57–60 Ravindran, Sanuj K. Biotechnology in India: Just What the Doctor Outsourced? June: 43–47 Silverman, Ed. What Do Payers Really Want To See? April: 43–46 Silverman, Ed. Business Savvy in the Age of Biologics. Aug.: 49–52 Stevens, Kevin; Johnson, Anthony. Lower Cost and Faster Product Approval Through Proper Software Design Controls. Dec.: 54–57 Wilson, Chantell L.; Schultz, Stephanie; Waldman, Scott A. Cancer Biomarkers: Where Medicine, Business, and Public Policy Intersect. Feb.: 33–42 the Doctor Outsourced? June: 43–47 Convergence in the Midst of Competition. Dec.: 31–32, 38–40 Biopharmaceuticals: The Economic Equation. Dec.: 41–45 Making an Impression on Biotech Development. Dec.: 60 Clinical Trials Budgetary Battles Burden Trial Funding. Aug.: 10–11 Devices ‘Natural Plastics’ Ripe With Potential. June: 11–12, 18 Ousting the “Ouch Factor” in Drug Delivery. Dec.:15–16 Lower Cost and Fast Product Approval Through Proper Software Design Controls. Dec.: 54–57 Drug Delivery Oral Oncologics Join the War on Cancer. June: 24–31, 38 Cancer Vaccines: A Century in the Making … Almost Here? Dec.: 22–30 Drug Development Biotech Proving a Formidable Provider to Pharma Innovation. Feb.: 68 Aptamers: The New Frontier in Drug Development? April: 31–36 The Changing HIV/AIDS Landscape: Where Do Biologics Fit In? April: 52–56 Will Biotechnology Keep the Heart Healthy? Aug.: 43–48 Traversing the Landscape of Project BioShield. Oct.: 7–8 A Renewed Emphasis on Therapeutic Angiogenesis Research for CAD. Oct.: 49–54 Employer Concerns 5 Things Employers Want To Know About Biologics. Oct.: 23–28 Evidence–Based Care The Impact of CED on Private Payers. April: 24–30 Follow–on Biologics/Biosimilars Generic Biopharmaceutical Drugs: An Economic and Policy Analysis. Feb.: 43–48 Debate on Follow-on Biologics Intensifies After Release of Report. June: 22 Where the Wall Will Fall First. Aug.: 26–32 Formularies Commercial Formularies Face Pressure To Go 4-Tier. June: 61 Genomics and Genetics Gene Therapy: Science in Slow Motion. Feb.: 55–60 AUTHORS OF FEATURE ARTICLES Adams, Katherine T. Cancer Carveouts: Is It Time? Feb.: 24–32 Adams, Katherine T. Oral Oncologics Join the War on Cancer. June: 24–31, 38 Adams, Katherine T. Will Biotechnology Keep the Heart Healthy? Aug.: 43–48 Adams, Katherine T. Cancer Vaccines: A Century in the Making … Almost Here? Dec.: 22–30 Atkinson, William. The Impact of CED on Private Payers. April: 24–30 Atkinson, William. 5 Things Employers Want To Know About Biologics. Oct.: 23–28 Blackstone, Erwin A.; Fuhr, Joseph P. Generic Biopharmaceutical Drugs: An Economic and Policy Analysis. Feb.: 43–48 Blackstone, Erwin A.; Fuhr, Joseph P. Biopharmaceuticals: The Economic Equation. Dec.: 41–45 Butcher, Lola. The Changing HIV/AIDS Landscape: Where Do Biologics Fit In? April: 52–56 Butcher, Lola. PA No More? Aug.: 53–56 Carroll, John. Gene Therapy: Science in Slow Motion. Feb.: 55–60 Carroll, John. The World of Stem Cell Therapy: Anonymity Is Not an Option. June: 54–58 Carroll, John. Where the Wall Will Fall First. Aug.: 26–32 Carroll, John. Biogenetic Tests Emerge From Their Chrysalis. Oct.: 37–44 Carroll, John. Convergence in the Midst of Competition. Dec.: 31–32, 38–40 Carlson, Bob. Aptamers: The New Frontier in Drug Development? April: 31–36 Articles may be read at BIOTECHNOLOGY HEALTHCARE’S Web site: «www.biotechnologyhealthcare.com» TOPICS Adherence and Compliance Taking Control of Compliance. June: 39–42 Benefit Design Cancer Carve-outs: Is It Time? Feb.: 24–32 Biologics Provide Hope for Immune System Disorders. Oct.: 55–58 Employers Work To Manage Biologics in 2008 Benefit Design. Dec.: 20–21 Biomarkers Cancer Biomarkers: Where Medicine, Business, and Public Policy Intersect. Feb.: 33–42 Biotechnology Industry Biotechnology in India: Just What 62 BIOTECHNOLOGY HEALTHCARE · MAY/JUNE 2008 http://www.biotechnologyhealthcare.com
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.